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the association with neutrophil engraftment, acute and
chronic graft-versus-host disease, TRM, and relapse. Patient,
disease, and HCT-related characteristics were compared
by chi-square statistic for categorical variables and the
Kruskal-Wallis test for continuous variables.
Results: Increased expression of the CTRA gene proﬁle is
associated with increased relapse at 3 years post-HCT
(p¼.04; Figure 1) and decreased LFS overall (p¼.04; Figure 2).
There were no signiﬁcant outcome differences based on SES
in this sample. HCT recipients of high SES lived closer to the
transplant center (p<.001) while recipients with higher
CTRA gene expression proﬁles were younger (p¼.04) and
were infused with lower doses of peripheral blood cells
(p.02). All other patient, disease, and demographic
variables were equal between groups.
Conclusions: Exposure to socioeconomic adversity is
associated with a marked pro-inﬂammatory/anti-antiviral
shift in the PBMC transcriptome and this shift in gene
expression is reciprocally related to adverse clinical
outcomes including increased relapse and decreased LFS.67
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The NIH chronic GVHD (cGVHD) Consensus Project
Ancillary and Supportive Care Guidelines prescribe yearly
monitoring of bone mineral density (BMD) based on prac-
tices in other chronic diseases. We hypothesize that patients
with cGVHD have a high incidence of osteoporosis due to
additive risk factors including inﬂammation, hypogonadism,
malnutrition, and chronic steroid use. A large group of
cGVHD patients was analyzed to determine the prevalence of
osteoporosis and characterize risk factors.
258 cGVHD patients were enrolled in the NIH/NCI Natural
History protocol (NCT00092235), a cross-sectional study
where patients undergo a one-week comprehensive
evaluation including DEXA. T-scores were calculated at the
femoral neck (FN), lumbar spine (LS), and total hip (TH).
Osteoporosis was deﬁned by BMD (T-score -2.5). Patients
were placed into 2 groups, osteoporosis and non-
osteoporosis and analyzed for factors associated with
osteoporosis initially by standard univariate statistical tests;
p values<0.005 were considered statistically signiﬁcant
while tests with 0.005<p<0.05 exhibited strong trends
towards statistical signiﬁcance. Multivariable analyses were
performed using multiple logistic regression analysis.
Patients (145 M, 113 F) with median age of 48 years (20-
71), enrolled a median of 692 days (0-6670) after cGVHD
diagnosis, with a median of 5 affected organs (1-8), received
a median of 4 prior systemic therapies (0-9), and a medianequivalent prednisone dose of 0.078mg/kg (0-3.38). 183
patients (71%) had severe, 73 (28%) moderate, and 2 (1%)
mild cGVHD by NIH Global score. 42 (16%) patients had
osteoporosis in at least 1 location with incidence highest at
the FN (33; 13%) followed by LS (24; 9%) and TH (15; 6%).
Female gender (FN: p¼0.04), lower weight (FN: p<0.0001;
LS: p¼0.0002; TH: p<0.0001), higher platelet count (FN:
p¼0.007; TH: p¼0.003), higher NIH average organ score (FN:
p¼0.04), higher prednisone dose (LS: p¼0.03), and lower C3
(LS: p¼0.007) were associated with osteoporosis. Factors not
associated included age, vitamin D3, estradiol, FSH, LH,
testosterone, number of prior systemic therapies, among
others. Multiple logistic regression analyses determined that
BMI, prednisone dose, and number of prior regimens were
potentially predictive for spinal osteoporosis, while FN and
TH osteoporosis were potentially predictable by weight and
platelet counts.
Prevalence of osteoporosis was high (16%) which supports
current recommendations of regular BMD monitoring.
Classic risk factors such as age, hypogonadism, and steroid
use were not found to be signiﬁcantly associated, factors
reﬂecting more severe disease and inﬂammation such as low
weight and elevated platelets were found to be associated.
This suggests a need to focus on cGVHD control as a means to
prevent osteoporosis, a hypothesis which needs further
testing in prospective studies.68
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Chronic GVHD (cGVHD) is a frequent complication of
allogeneic hematopoietic stem cell transplantation (HSCT)
and affects multiple organ systems, with the oral cavity being
one of the most frequently affected sites. Patients with
cGVHD experience reduced quality of life (QOL), yet the
speciﬁc impact of oral cGVHD on QOL is poorly understood.
The objective of this study was to characterize the impact of
oral cGVHD on global measures of QOL.
Methods: QOL data were collected using the FACT-BMT and
SF-36 instruments for 569 patients enrolled in the Chronic
GVHD Consortium, with a total of 1,915 follow-up visits. At
study enrollment, patients were categorized as isolated oral
cGVHD (n¼22), oral and concomitant extra-oral cGVHD
(n¼420), and only extra-oral cGVHD (n¼127). Utilizing all
longitudinal data, QOL scores were compared using a
multivariable linear model controlling for demographic,
transplant, and cGVHD characteristics.
Results: Patients with isolated oral cGVHD reported better
physical well-being (P¼0.009), BMT well-being (P¼0.01),
and decreased bodily pain (P¼0.01) compared to patients
with oral and concomitant extra-oral cGVHD. A similar trend
was observed that patients with isolated oral cGVHD
reported better physical well-being (P¼0.02) and less bodily
pain (P¼0.02) compared to patients with only extra-oral
cGVHD. QOL scores were similar in several domains, most
notably social/family well-being, physical role functioning,
and vitality, when comparing patients with isolated oral
cGVHD to patients with oral and concomitant extra-oral
cGVHD and only extra-oral cGVHD.
Table 1
Multivariable analysis comparing quality of life scores
Isolated oral vs. oral and extra-oral Isolated oral vs. only extra-oral
Difference in QOL scores between groups p-value Difference inQOL scoresbetween groups p-value
FACT-BMT
total 3.14 0.03 1.58 0.32
physical well-being 1.09 0.009 1.09 0.02
social/family well-being 0.17 0.63 -0.13 0.75
emotional well-being 0.45 0.14 0.07 0.85
functional well-being 0.88 0.05 0.29 0.56
BMT well-being 1.10 0.01 0.81 0.10
SF-36
PCS 1.20 0.14 1.08 0.23
MCS 0.17 0.85 -0.67 0.50
physical functioning 0.96 0.25 0.79 0.39
physical role functioning -0.29 0.76 -0.52 0.62
bodily pain 2.26 0.01 2.43 0.02
general health perceptions 1.62 0.05 0.22 0.81
vitality 0.07 0.94 -0.50 0.60
social role functioning 1.29 0.21 0.81 0.47
emotional role functioning 0.46 0.67 -0.72 0.54
mental health 0.27 0.75 -0.43 0.64
BMT¼ bone marrow transplant, PCS¼ physical component score, MCS¼ mental component score.
Table 1
Predictors of Preventive Care Adherence (N¼387 in Logistic Regression)
OR (95%CI) P value
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S78Conclusions: Isolated oral cGVHD is associated with
better QOL compared to extra-oral cGVHD across multiple
domains, in particular physical well-being and bodily pain.Gender <.001
Male referent
Female 4.64 (2.78-7.76)
cGVHD History .002
None-mild referent
Moderate-severe 2.29 (1.37-3.85)
Financial Barriers .03
No referent
Yes 2.30 (1.08-4.90)
Side Effects Barriers .02
No referent
Yes 2.28 (1.15-4.52)
Time Constraints Barriers .02
No referent
Yes 2.25 (1.12-4.52)
SF-36 Physical Component T score 1.03 (1.01-1.06) .01
Conﬁdence in Survivorship Information 0.36 (.21-.60) <.00169
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Introduction: HCT survivors require long-term surveillance
and preventive care to reduce the late effects of treatment.
We examined demographic, treatment and psychosocial
factors associated with preventive care adherence (PCA) in a
national sample of survivors recruited for an online RCT.
Method: Four email invitations to participate were sent to
HCT survivors on the BMT InfoNet listserve, a patient
resource and advocacy site. Eligibility criteria included
18 years old, more than two years post-HCT, without a
recurrence or second cancer in the prior two years, able to
communicate in English, and with internet and email access.
Measures were the Short Form-36 physical component scale
(PCS), Symptom Checklist-90-R depression, Cancer and
Treatment Distress, Katz Comorbidity Index, Conﬁdence in
Survivorship Information (CSI) about recommended PCA
tests for HCT survivors, and Barriers to PCA. Multivariate
logistic regression was used to analyze factors associated
with not meeting PCA criteria for at least 75% of 15 exams.
Results: Of 493 registered survivors, 395 (80%) were eligible
for analysis. Participants were from the U.S. (93%, N¼368)
and 12 other countries, treated at 142 centers, largelyCaucasian and non-Hispanic (94%), on average 9 years
post-HCT (SD¼6, range 2-33); 67% received allogeneic HCT,
38% reported a history of moderate to severe chronic graft
versus host disease (cGVHD). The percentage of survivors
who did not meet recommended criteria on 75% of the 15
potential PCA tests was 37% (N¼147). Age, race and ethnicity,
years post-transplant, comorbidities, depression and
distress were not associated with PCA (P’s >.05). Table 1
indicates the odds ratios and conﬁdence intervals for
factors associated with PCA in the ﬁnal model including:
gender, cGVHD history, SF-36 PCS T scores, CSI, and 3 types
of barriers: ﬁnancial, concerns about side effects, and time
constraints.
Discussion: Over a third of HCT long-term survivors inter-
ested in an online RCT did not meet PCA recommendations,
indicating need for improved dissemination of preventive
guidelines. Those needing targeted approaches to improve
PCA include males, those doing better in physical function
and lack of cGVHD history, and those with deﬁnable barriers
to health care.
